Clinical Trials with Immunotoxins
$854,104ZIAFY2017CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications & trials
Paper 34030585Paper 33627164Paper 32077130Paper 31944549Paper 31792036Paper 31628266Paper 30538953Paper 30030507Paper 29143114Paper 28286803Paper 28013405Paper 27863199Paper 26463707Paper 24824231Paper 22355053Paper 22351743Paper 22339074Paper 22149739Paper 22069706Paper 22003067Paper 21998010Paper 21599609Paper 21504287Paper 21037025Paper 20215554Paper 19898744Paper 19814696Paper 19744744Paper 19671873Paper 19414673Paper 18678888Paper 16857795Paper 16681430Paper 16675574Paper 16638849Paper 16428485Paper 16311729Paper 16082249Paper 16061911Paper 15701286Paper 15217923Paper 14734446
Abstract
A phase 3 trial evaluating its activity in patients with chemo-resistant hairy cell leukemia (HCL) has been completed. The response rate is very high with many complete and partial remissions lasting 6 months or more. There have been no major side effects. The data will be submitted to the FDA this year. For mesothelioma therapy we are evaluating a new genetically engineered immunotoxin (LMB-100) in patients with mesothelin expressing malignancies in collaboration with Drs. Raffit Hassan and Christine Alewine.
View original record on NIH RePORTER →